1. Abernethy, D. R., Diroll, M., Ochs, H. R., et al. (1982). Increased metabolic clearance of aceta-minophen with oral contraceptive use, Obst. Gynecol. 60, 338–341.
2. Abernethy, D. R., Ameer, B. and Greenblatt, D. J. (1984). Probencid inhibition of acetaminophen and lorazepamglucuronidation, Clin. Pharmacol. Ther. 35, 224.
3. Acevedo, E., Romanowicz, A., Van der Heyde, D., et al. (1999). Rofecoxib, a COX-2 specific inhibitor (C-251), had a clinical efficacy comparable to diclofenac on the treatment of knee and hip osteoarthritis (OA) in a one-year controlled trial, Ann. Rheum. Dis. (EULAR), p. 206, Abstract 858.
4. Adams, M. E. (1993). An analysis of clinical studies of the use of cross-linked hyaluronan–hylan in the treatment of osteoarthritis, J. Rheumatol. 22 (Suppl. 39), 15–17.
5. Adams, M. E., Atkinson, M. H., Lussier, A. J., et al. (1995). The role of viscosupplementationwith hylan G-F20 (Synvisc ® ) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial company hylan G-F20 alone, hylan G-F20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone, Osteoarthritis and Cartilage 3, 213–225.